The expert panel shares clinical pearls for treatment and management of Spinal Muscular Atrophy. O painel de especialistas compartilha recomendações valiosas para o tratamento e manejo da atrofia muscular espinhal.
Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
The professor of clinical neurology at University of Miami and MT2020+ chair, and president of Medtronic's Neurovascular Business discussed the effort to improve global accessibility of mechanical thrombectomy.
The division chief of stroke and vascular neurology at Duke Health provided perspective on the multidisciplinary team needed to treat neuromuscular poststroke symptoms, as well as exciting innovations on the horizon. [WATCH TIME: 4 minutes]
The neurologist from the University of Washington Medical Center discussed the findings of her recent study presented at ACTRIMS Forum 2021.
The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.
Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.
Key opinion leaders review the study design and mechanisms of action for drugs in ongoing clinical trials and consider the future of amyotrophic lateral sclerosis (ALS).
The director of the Stanford Stroke Center and Coyote Foundation Professor of Neurology and Neurological Sciences at Stanford Medical Center shared his perspective on the uptake of mobile stroke units across the United States. [WATCH TIME: 6 minutes]
The neurologist and physician scientist at Washington University in St. Louis provided perspective on the need for additional studies assessing the long-term effects of dieting strategies in multiple sclerosis. [WATCH TIME: 3 minutes]
The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]
The assistant professor of clinical pediatrics at Indiana University School of Medicine, and the chair of the AASM’s Artificial Intelligence in Sleep Medicine Committee, spoke about the ability of AI algorithms as tools in clinical care. [WATCH TIME: 3 minutes]
In a time when complex medical communication to the public is on display, the need to ensure patient comprehension is of utmost importance for vascular neurologists.
Fatigue, although not immediately visible, is among the most debilitating symptoms of multiple sclerosis, affecting not only patients' day-to-day functioning but their quality of life.
Advocacy organization Cure SMA provides insight on the importance of continuing to push for standardized newborn screening and how it can positively impact outcomes in SMA.
Ahead of the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas, the vice president of public policy and advocacy at the Muscular Dystrophy Association provided an overview of the current state of access and the need for more advocates in neuromuscular disease. [WATCH TIME: 14 minutes]
The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]
The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
The duo from MedStar Georgetown University Hospital detailed the need for education on Parkinson disease and movement disorder therapies, and the CME activities they’ve developed with the PMD Alliance to address those needs. [WATCH TIME: 5 minutes]
The assistant professor at Cleveland Clinic provided thoughts on the barriers clinicians face when formulating and conducting Alzheimer disease clinical trials with repurposed drugs.
Episode 24 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Joseph R. Berger, MD, of the University of Pennsylvania. [WATCH TIME: 7 minutes]
The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.
The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
The clinical professor at the University at Buffalo discussed the complexities of using combination therapies to treat myasthenia gravis, and whether adverse events play a major role in treatment decisions. [WATCH TIME: 3 minutes]
The graduate student at the University of Michigan provided insight on her study examining longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders. [WATCH TIME: 3 minutes]
Expert neurologists provide insight on unmet needs, challenges to improve access to care, and highlight clinical pearls for the management of OFF episodes in Parkinson disease.
The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.
The duo from Montefiore Medical Center discussed aspects of their recently published recommendations on neonatal seizure diagnosis that need further examining.
Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.
A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.